Norm MacDonald on battles with cancer: “I’m pretty sure, I’m not a doctor, but I’m pretty sure if you die, the cancer dies at the same time. That’s not a loss. That’s a draw.”
Recruit for #ICECAP at AAH sites begins this week. Interesting to see how the trial will compare to TTM2. Today’s presentation maybe practice changing for many. #TTM2trial
Will await the final print but RECOVERY trial demonstrates improved outcomes in those receiving tocilizumab. This is consistent with prior trials as well as trials using both toci and dexamethasone. medrxiv.org/content/10.1101/…
There is an enormous demonstration going on at @Stanford Hospital right now carried out by staff, who are protesting the decision by higher ups to give vaccines to some administrators and physicians who are at home and not in contact with patients INSTEAD of frontline workers.
Winter Panel Series opens this week with a discussion on EM Critical Care Wed @7pm
featuring
@DavidBarounis, ACMC grad and medical director of ICU
@jstancc, ACMC grad and intensivist
@ma5880 PGY3, Northwestern critical care fellowship bound
RSVP to Angelica.Flores@aah.org
Thank you to all the residents that helped out during the initial wave of patients in mid-March. Thank you to Dr. Mukai for giving this lecture at ICEP!
@ACMCEM@ACMCIMRes@advocatehealth
Thank you @ACMCEM for allowing me to tell the evolving story about our experience with #covid19 So many people have been involved in keeping our patients safe while supporting each other through difficult times @advocatehealth@DoddMD@RajuMehtaMD@ngoodmanson
Early use of tocilizumab appears to show a reduction in a composite endpoint of mortality need for mechanical ventilation. We’re working on RCT data now @DoddMD @AdvocateAurora @RajuMehtaMD thelancet.com/journals/lanrh…
1/2 Part of our strategy from the beginning has been looking at the implementation of steroids in patients with #COVID19. We followed the DEXA-ARDS trial, and after intense internal debate, we adopted the approach based on crude inflammatory markers and
2/2 development of hypoxemia. There is more to this story, but it is plausible this accounts for a portion of the results we have seen. Thank you to our AIP team!
@advocatehealth@RajuMehtaMD@DoddMD@ngoodmanson@ECMOeydelman @AdvocateAurora
Great webinar today thanks to all!
Early Advocate Christ experience for patients on ECLS.
-Average age was 49
-Only 12% had renal failure
-Average P/F ratio 65
-Still 18 in the icu but EARLY survival has been 89%
@ELSOOrg@DoddMD@DoddMD@PulmCrit @covid19foam @SCCM@SPauwaa